Crinetics Pharmaceuticals (CRNX) Competitors $31.90 +0.07 (+0.22%) Closing price 04:00 PM EasternExtended Trading$32.08 +0.18 (+0.56%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CRNX vs. RDY, VTRS, QGEN, ASND, BBIO, VRNA, BPMC, ROIV, ELAN, and RGCShould you be buying Crinetics Pharmaceuticals stock or one of its competitors? The main competitors of Crinetics Pharmaceuticals include Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Qiagen (QGEN), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), and Regencell Bioscience (RGC). These companies are all part of the "pharmaceutical products" industry. Crinetics Pharmaceuticals vs. Its Competitors Dr. Reddy's Laboratories Viatris Qiagen Ascendis Pharma A/S BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Roivant Sciences Elanco Animal Health Regencell Bioscience Crinetics Pharmaceuticals (NASDAQ:CRNX) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk. Do analysts prefer CRNX or RDY? Crinetics Pharmaceuticals currently has a consensus target price of $69.50, indicating a potential upside of 117.87%. Dr. Reddy's Laboratories has a consensus target price of $16.95, indicating a potential upside of 15.84%. Given Crinetics Pharmaceuticals' higher probable upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Crinetics Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80Dr. Reddy's Laboratories 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more volatility and risk, CRNX or RDY? Crinetics Pharmaceuticals has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Do institutionals & insiders have more ownership in CRNX or RDY? 98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is CRNX or RDY more profitable? Dr. Reddy's Laboratories has a net margin of 17.38% compared to Crinetics Pharmaceuticals' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 17.98% beat Crinetics Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Crinetics PharmaceuticalsN/A -30.95% -28.12% Dr. Reddy's Laboratories 17.38%17.98%12.24% Does the media prefer CRNX or RDY? In the previous week, Crinetics Pharmaceuticals had 7 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 10 mentions for Crinetics Pharmaceuticals and 3 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.02 beat Crinetics Pharmaceuticals' score of 0.42 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dr. Reddy's Laboratories 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, CRNX or RDY? Dr. Reddy's Laboratories has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCrinetics Pharmaceuticals$1.04M2,871.92-$298.41M-$3.82-8.35Dr. Reddy's Laboratories$3.81B3.21$663M$0.6622.17 SummaryDr. Reddy's Laboratories beats Crinetics Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRNX vs. The Competition Export to ExcelMetricCrinetics PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.98B$2.45B$5.57B$9.31BDividend YieldN/A1.79%4.23%4.03%P/E Ratio-8.359.1928.6119.73Price / Sales2,871.92587.68412.31173.11Price / CashN/A164.3436.0257.96Price / Book2.234.698.235.67Net Income-$298.41M$30.99M$3.23B$257.79M7 Day Performance-1.33%0.60%-0.01%0.52%1 Month Performance2.24%7.93%5.61%8.84%1 Year Performance-41.98%-5.48%26.52%14.18% Crinetics Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRNXCrinetics Pharmaceuticals3.4423 of 5 stars$31.90+0.2%$69.50+117.9%-41.2%$2.98B$1.04M-8.35210RDYDr. Reddy's Laboratories2.7723 of 5 stars$14.58+0.4%$16.95+16.3%-9.5%$12.17B$325.54B22.0827,811VTRSViatris2.9016 of 5 stars$9.14+0.2%$10.40+13.8%-18.8%$10.73B$14.74B-2.8832,000News CoverageQGENQiagen3.6956 of 5 stars$48.25+0.3%$49.40+2.4%+16.7%$10.73B$1.98B120.985,765Positive NewsASNDAscendis Pharma A/S3.7208 of 5 stars$174.880.0%$223.07+27.6%+27.5%$10.69B$393.54M-27.851,017BBIOBridgeBio Pharma4.6355 of 5 stars$47.69+2.6%$61.20+28.3%+68.7%$9.06B$221.90M-13.51400Analyst ForecastAnalyst RevisionVRNAVerona Pharma PLC American Depositary Share2.2752 of 5 stars$104.67-0.2%$109.00+4.1%+387.3%$8.91B$42.28M-52.3430Analyst ForecastHigh Trading VolumeBPMCBlueprint Medicines1.104 of 5 stars$129.36+0.0%$128.25-0.9%+8.2%$8.35B$508.82M-52.37640Positive NewsHigh Trading VolumeROIVRoivant Sciences2.7913 of 5 stars$11.63+2.4%$16.50+41.9%-1.2%$7.91B$29.05M-46.52860ELANElanco Animal Health1.4938 of 5 stars$14.88-0.2%$15.33+3.1%+9.4%$7.39B$4.44B20.109,000RGCRegencell Bioscience0.3368 of 5 stars$14.68-0.5%N/AN/A$7.29BN/A0.0010Positive NewsGap Up Related Companies and Tools Related Companies Dr. Reddy's Laboratories Competitors Viatris Competitors Qiagen Competitors Ascendis Pharma A/S Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Blueprint Medicines Competitors Roivant Sciences Competitors Elanco Animal Health Competitors Regencell Bioscience Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRNX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett’s Little-Known Succession PlanYou could miss out on millions buying a house - even if prices rise Joel Litman is a millionaire member of ...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
